Cargando…

Seroprevalence of Human Papillomavirus Types 6, 11, 16 and 18 in Chinese Women

BACKGROUND: Human papillomavirus (HPV) seroprevalence data have not previously been reported for different geographical regions of China. This study investigated the cross-sectional seroprevalence of antibodies to HPV 6, 11, 16, and 18 virus-like particles in Chinese women. METHODS: Population-based...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ji, Jia, Sun, Hai-Kui, Smith, Jennifer S, Wang, He, Esser, Mark T, Hu, Shangying, Pretorius, Robert G, Chen, Wen, Belinson, Jerome L, Qiao, You-Lin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2012
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3482566/ https://www.ncbi.nlm.nih.gov/pubmed/22715915 http://dx.doi.org/10.1186/1471-2334-12-137

Ejemplares similares

Seroprevalence of HPV 6, 11, 16 and 18 and correlates of exposure in unvaccinated women aged 16–64 years in Puerto Rico
por: Ortiz, A.P., et al.
Publicado: (2018)

Seroprevalence of HPV serotypes 6, 11, 16 and 18 in unvaccinated children from Mexico City
por: Pacheco-Domínguez, Reyna Lizette, et al.
Publicado: (2019)

The prevalence and distribution of human papillomavirus among 10,867 Chinese Han women
por: Guo, Chunlei, et al.
Publicado: (2021)

Safety of human papillomavirus 6, 11, 16 and 18 (recombinant): systematic review and meta-analysis
por: Coelho, Pedro Luiz Spinelli, et al.
Publicado: (2015)

Cost-effectiveness analysis of AS04-adjuvanted human papillomavirus 16/18 vaccine compared with human papillomavirus 6/11/16/18 vaccine in the Philippines, with the new 2-dose schedule
por: Germar, Maria Julieta, et al.
Publicado: (2017)

Evaluation of alternately combining HPV viral load and 16/18 genotyping in secondary screening algorithms
por: Luo, Hongxue, et al.
Publicado: (2019)

Seroprevalence of human papillomavirus-16, -18, -31, and -45 in a population-based cohort of 10 000 women in Costa Rica
por: Wang, S S, et al.
Publicado: (2003)

Modeling the impact of the difference in cross-protection data between a human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and a human papillomavirus (HPV)-6/11/16/18 vaccine in Canada
por: Kohli, Michele, et al.
Publicado: (2012)

Detection of Human Papillomavirus Types 6/11, 16 and 18 in Exfoliated Cells from the Uterine Cervices of Japanese Women with and without Lesions
por: Yokota, Harushige, et al.
Publicado: (1990)

Prevention of cervical, vaginal, and vulval cancers: role of the quadrivalent human papillomavirus (6, 11, 16, 18) recombinant vaccine
por: Diaz, Maria Lina
Publicado: (2010)

Simultaneous Detection and Differentiation of Human Papillomavirus Genotypes 6, 11, 16 and 18 by AllGlo Quadruplex Quantitative PCR
por: Yu, Daojun, et al.
Publicado: (2012)

A novel vaccine for cervical cancer: quadrivalent human papillomavirus (types 6, 11, 16 and 18) recombinant vaccine (Gardasil(®))
por: Govan, Vandana A
Publicado: (2008)

Quadrivalent Human Papillomavirus (HPV) Types 6, 11, 16, 18 Vaccine for the Prevention of Genital Warts in Males: Profile Report
por: Garnock-Jones, Karly P., et al.
Publicado: (2012)

Antibodies to human papillomavirus types 6, 11, 16 and 18: Vertical transmission and clearance in children up to two years of age
por: Zahreddine, Monica, et al.
Publicado: (2020)

Burden of Human Papillomavirus (HPV)-Related Cancers Attributable to HPVs 6/11/16/18/31/33/45/52 and 58
por: de Sanjosé, Silvia, et al.
Publicado: (2019)

Prevalence and Seroprevalence of Low-Risk Human Papillomavirus in Korean Women
por: Kim, Min-A, et al.
Publicado: (2012)

Immunogenicity and safety of the AS04-HPV-16/18 and HPV-6/11/16/18 human papillomavirus vaccines in asymptomatic young women living with HIV aged 15–25 years: A phase IV randomized comparative study
por: Folschweiller, Nicolas, et al.
Publicado: (2020)

Human papillomavirus 16/18 seroprevalence in unvaccinated women over 30 years with normal cytology and with high grade cervical abnormalities in Australia: results from an observational study
por: Velentzis, Louiza S, et al.
Publicado: (2014)

Comparison of long-term immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18-45 years: End-of-study analysis of a Phase III randomized trial
por: Einstein, Mark H, et al.
Publicado: (2014)

High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up
por: Villa, L L, et al.
Publicado: (2006)

Progression and regression of incident cervical HPV 6, 11, 16 and 18 infections in young women
por: Insinga, Ralph P, et al.
Publicado: (2007)

Whole-Genome Analysis of Human Papillomavirus Types 16, 18, and 58 Isolated from Cervical Precancer and Cancer Samples in Chinese Women
por: Liu, Ying, et al.
Publicado: (2017)

Comparative humoral and cellular immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18–45 years: Follow-up through Month 48 in a Phase III randomized study
por: Einstein, Mark H, et al.
Publicado: (2014)

Sexual behavior and infection with cervical human papillomavirus types 16 and 18
por: Itarat, Yuwadee, et al.
Publicado: (2019)

Antibodies to Human Papillomavirus 16, 18, 58, and 6b Major Capsid Proteins among Japanese Females
por: Matsumoto, Koji, et al.
Publicado: (1997)

Human papillomavirus seroprevalence and seroconversion following baseline detection of nine human papillomavirus types in young women
por: Brown, Darron R., et al.
Publicado: (2022)

Human papillomavirus type 18 is associated with less apoptosis in fibroblast tumours than human papillomavirus type 16.
por: Arends, M. J., et al.
Publicado: (1995)

Stability of trivalent human papillomavirus (types 16, 18, 58) recombinant vaccine (Escherichia coli)
por: Liu, Yu-Ying, et al.
Publicado: (2021)

Incident HPV 51 Infection After Prophylactic Quadrivalent Human Papillomavirus (Types 6, 11, 16, and 18) L1 Virus-Like Particle Vaccine Gardasil/Silgard(®)
por: Halfon, Philippe, et al.
Publicado: (2010)

Cost Effectiveness of Human Papillomavirus-16/18 Genotyping in Cervical Cancer Screening
por: Huh, Warner K., et al.
Publicado: (2014)

Persistence of human papillomavirus 16, 18 and 52 variants in Inuit women from Northern Quebec, Canada
por: Gauthier, Barbara, et al.
Publicado: (2019)

Searching for the methylation sites involved in human papillomavirus type 16 and 18‑positive women with cervical cancer
por: Ma, Yanyun, et al.
Publicado: (2022)

Genetic Variability in the E6, E7, and L1 Genes of Human Papillomavirus Types 16 and 18 among Women in Saudi Arabia
por: Alsanea, Madain, et al.
Publicado: (2022)

Safety and immunogenicity of human papillomavirus-16/18 AS04-adjuvanted vaccine in healthy Chinese females aged 15 to 45 years: a phase I trial
por: Zhu, Feng-Cai, et al.
Publicado: (2011)

The seroprevalence of human papillomavirus by immune status and by ethnicity in London
por: Casabonne, Delphine, et al.
Publicado: (2009)

Detection of High-Risk Human Papillomavirus in Cervix Sample in an 11.3-year Follow-Up after Vaccination against HPV 16/18
por: Teixeira, Cirbia Silva Campos, et al.
Publicado: (2017)

Detection of human papillomavirus-16 in ovarian malignancy
por: Wu, Q-J, et al.
Publicado: (2003)

Kinetics and isotype profile of antibody responses in rhesus macaques induced following vaccination with HPV 6, 11, 16 and 18 L1-virus-like particles formulated with or without Merck aluminum adjuvant
por: Ruiz, Wanda, et al.
Publicado: (2005)

Human papillomavirus types 16 and 18 and the prognosis of patients with stage I cervical cancer
por: de Araújo Catão Zampronha, Rossana, et al.
Publicado: (2013)

Prevalence of Human Papillomavirus subtypes 16 and 18 among Yemeni Patients with Cervical Cancer
por: Ahmed, Hussain Gadelkarim, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_10vla1begj1mkpeofnjc9r8meu